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Inhibition of radiographic progression of structural joint damage at year 1 and year 2 by original randomization. The LS mean change from baseline (±SEM) in structural joint damage evaluated using (A) mTSS, (B) ES, and (C) JSN for patients in RA-BEYOND originally completing RA-BEGIN, RA-BEAM, or RA-BUILD. Time points represent time from randomization in the originating studies. Indicated treatment groups are according to randomization in the originating study ('initial' denotes initial randomized treatment group). Patients on PBO, MTX, or ADA in the originating studies switched to baricitinib 4 mg at rescue or at 24 weeks (PBO; single arrow) or 52 weeks (MTX and ADA; double arrow) as detailed in the study design. Tables represent the number of patients for whom data were available for each time point and study. Comparisons were analysed using a mixed model for repeated measures. Missing scores at 2 years were imputed using linear extrapolation based on data collected between 1 and 2 years. ADA, adalimumab; Bari, baricitinib; ES, erosion score; JSN, joint space narrowing; LS, least squares; mTSS, modified total Sharp score; MTX, methotrexate; PBO, placebo; RA, rheumatoid arthritis; SEM, SE of the mean *p≤0.05, **p≤0.01, ***p≤0.001 baricitinib 4 mg vs PBO (RA-BEAM; RA-BUILD) or MTX (RA-BEGIN); + p≤0.05, ++ p≤0.01, +++ p≤0.001 ADA vs PBO (RA-BEAM); ‡p≤0.05 baricitinib 4 mg vs baricitinib 4 mg plus MTX (RA-BEGIN).
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